Deal Snapshot
LUPIN ACQUIRES US BIOTECH SYMBIOMIX THERAPEUTICS FOR USD 150M
Thursday 12 October 2017

US-based pharmaceutical company Lupin, Inc. has acquired New Jersey, US-based biotechnology firm Symbiomix Therapeutics, LLC for USD 150m, the company said.

Lupin, Inc. is a US subsidiary of India-based pharma major Lupin. The acquisition has been made for a cash consideration of USD 150m including a USD 50m upfront and other time-based payments. In addition, there are sales based contingent payments. The acquisition is funded from internal funds. The acquisition of Symbiomix and the Solosec franchise expands Lupin's branded women's health specialty business, which is presently anchored by Methergine (methylergonovine) tablets.


TKUqg0 http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com
Details
Date Published: 12/10/2017
Target: Symbiomix Therapeutics
Country: USA
Deal Size: 150m (USD)
Sector: Biotechnology
Type: Corporate acquisition
Financing: Cash
Status: Closed
Vendor:
Buyer: Lupin, Inc
Comment:


Options